Abstract. Hypoxia regulates the expression of genes that promote tumor growth, angiogenesis and invasion. We previously studied hypoxic tumor cells in vitro and from hepatic metastases of colorectal cancer and determined several potential prognostic factors for hepatocellular carcinoma (HCC). In this study, we evaluated the prognostic impact of the expression of ephrin-A1 (EFNA1) and its receptor, EPHA2, in patients with HCC after curative resection. Samples from a total of 139 HCC patients were analyzed by either microarray alone (n=86) or by microarray and quantitative PCR (n=53). There was no correlation between EFNA1 expression and clinicopathological factors. EPHA2 expression was not significantly correlated with any clinicopathological factors, except for microscopic portal invasion. EFNA1 was an independent prognostic factor for HCC (p=0.0277). These findings suggest that EFNA1 expression may be a useful marker for predicting high risk of recurrence in patients who have undergone curative resection for HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignancies and the fifth leading cause of cancer-related death worldwide. Despite recent advances in diagnostic technology and new therapeutic modalities for HCC, the prognosis for patients with advanced-stage HCC is still poor (1) . Thus, it is crucial to find novel cancer-related genes that may serve as diagnostic markers and molecular targets in HCC therapy, especially after curative treatment.
Hypoxia is a central feature of solid tumors, and it regulates the expression of a diverse group of genes that promote tumor growth, invasion, angiogenesis and cell survival (2) (3) (4) (5) . In tumor cells under hypoxic conditions, the hypoxia-inducible factor-1 (HIF-1) pathway is activated and leads to upregulation of many hypoxia-response genes, which are associated with an aggressive tumor phenotype (5-7). We previously reported that these hypoxia-related genes include several angiogenic factors that play important roles in cancer biology (3, (8) (9) (10) . The anti-VEGF antibody bevacizumab is used clinically for treatment of several human cancers (11) , and the multi-tyrosine kinase inhibitor sorafenib was shown to have survival benefits for patients with advanced HCC in two phase III clinical trials (12, 13) . These findings support the use of hypoxia-induced genes as clinically relevant therapeutic targets.
Ephrin-A1 (EFNA1) is known as an angiogenesis factor and is induced through an HIF-1-dependent pathway (14, 15) . EFNA1 was originally isolated as a secreted protein in conditioned media from cultures of human umbilical vein endothelial cells treated with tumor necrosis factor-α (16, 17) . Binding of EFNA1 ligand to its receptor EPHA2 promotes autophosphorylation, which triggers downstream signals that regulate cell growth and migration. EFNA1 expression has been observed in tumor cells and in endothelial cells and has been shown to induce endothelial cell migration (18) , capillary assembly in vitro and corneal angiogenesis in vivo (19) . EFNA1 and EPHA2 expression is associated with carcinogenesis, angiogenesis (18, (20) (21) (22) , and tumorigenesis in various types of cancer (23) (24) (25) (26) (27) (28) .
We previously reported that HIF1A expression is correlated with tumor angiogenesis in HCC and that high nuclear expression of HIF-1 is a significant predictive factor for recurrence after curative resection in HCC patients (9) . Previously, we detected several potential prognostic factors and therapeutic targets in hypoxic tumor cells from hepatic metastases of CRC in vivo (8) . Of the 3,000 genes ranked in the microarray data, the top 30 were identified as hypoxia-inducible genes. Among these hypoxia-inducible genes, Jumonji domain containing 1A (JMJD1A, also known as KDM3A) and procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) were novel prognostic factors of HCC (3, 10) . In these experiments, EFNA1 expression was highly induced in hypoxic regions of liver metastases. Thus, we hypothesized that EFNA1 expression Association between ephrin-A1 mRNA expression and poor prognosis after hepatectomy to treat hepatocellular carcinoma 
RNA extraction and real-time quantitative RT-PCR analysis.
Total RNA was extracted by a single-step method with TRIzol reagent (Life Technologies, Inc., Gaithersburg, MD, USA) at Osaka University. Complementary DNA (cDNA) was generated by using avian myeloblastosis virus reverse transcriptase (Promega, Madison, WI, USA), as described previously (3). Real-time monitoring of PCR reactions was performed with the LightCycler system (Roche Applied Science, Indianapolis, IN, USA) for quantification of mRNA expression, as described previously (29) . The housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal standard. The sequences of the GAPDH primers were as follows: sense primer, 5'-CAACTACATGGTTTACATGTTC-3' and antisense primer, 5'-GCCAGTGGACTCCACGAC-3'. EFNA1 primer sets were designed to flank one intron and were tested to ensure amplification of only cDNA to avoid amplification of possible contaminating genomic DNA. The sequences of these PCR primers were as follows: EFNA1 sense primer, 5'-TGCC GTCCGGACGAGACAGGC-3' and antisense primer, 5'-CTG GAGCCAGGACCGGGACTG-3'.
Microarray experiment. Microarray results were evaluated in accordance with previously described methods (30) . Briefly, total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the instructions supplied by the manufacturer. The integrity of RNA was assessed with Agilent 2100 Bioanalyzer and RNA 6000 LabChip kits (Yokokawa Analytical Systems, Tokyo, Japan). Only high-quality RNA was used for analysis. Seven RNA extractions from different normal liver tissue samples were mixed and used as the control reference. Next, 2 µg of total RNA was used to synthesize double-stranded cDNA that contained a promoter for T7 RNA polymerase. Amplified antisense RNA was synthesized by in vitro transcription of the cDNA templates using the Amino Allyl MessageAmp aRNA kit (Ambion, Austin, TX, USA). The reference and test samples were labeled with Cy3 and Cy5, mixed, and hybridized on a microarray covering 30,336 human probes (AceGene Human 30K; DNA Chip Research Inc. and Hitachi Software Engineering Company, Yokohama, Japan). The microarrays were scanned using ScanArray Lite, and signal values were calculated using DNASIS array software (Hitachi Software Engineering Company). The local background was subtracted from each spot, and the ratio of the intensity of fluorescence from the Cy5 channel to the intensity of fluorescence from the Cy3 channel was calculated for each spot. The ratio of expression levels of each gene was converted to a logarithmic scale (base 2), and the data matrix was normalized.
Statistical analysis. For clinicopathological analyses, study samples were divided into high-and low-expression groups based on the median EFNA1 mRNA expression levels in tumor tissue. All statistical analyses were carried out using the StatView J-5.0 program (Abacus Concepts, Inc., Berkeley, CA), USA. The post-operative period was measured from the date of surgery to the date of the last follow-up or death. Differences were estimated using Fisher's exact probability test. Survival curves were calculated by the Kaplan-Meier method and compared statistically using the log-rank test. To estimate relative risk (RR) and 95% confidence intervals (95% CI), univariate and multivariate analyses were performed using the Cox proportional hazards regression model. Data are reported as mean ± standard deviation. Mean values were compared using the Mann-Whitney test. A probability value of <0.05 was deemed to be statistically significant.
Results
Expression of EFNA1 under hypoxic conditions. First, we evaluated expression of EFNA1 under hypoxic conditions. EFNA1 was expressed in all four hepatoma cell lines and gradually increased under hypoxia in HuH7, HepG2 and Hep3B cell lines, but not in PLC/PRF/5 cells (Fig. 1) . This result suggests that hypoxic conditions are associated with increased EFNA1 expression in HCC.
Patient profiles. Next, we evaluated the expression of EFNA1 in clinical samples by using microarray analysis. The patients selected for microarray analysis included 113 (81.3%) men and 26 (18.7%) women. Twenty-six patients had hepatitis B virus infection, and 85 patients were positive for hepatitis C virus antibody. A total of 102 patients had a single tumor in the liver, and 65 patients had a tumor <3 cm in diameter. Macroscopic vascular invasion was seen in 15 patients. With regard to TNM staging, 96 patients (69.1%) were stage I, 31 patients (22.3%) were stage II, and 12 patients (8.6%) were stage III. The characteristics of the 139 patients are summarized in Table I .
Microarray analysis of EFNA1 mRNA expression. We examined the correlation between expression levels of EFNA1 and EPHA2 and the clinicopathological factors of the 139 HCC patients who had undergone hepatic resection. The 139 patients were divided into two groups, a high-expression group (n=70) and a low-expression group (n=69), based on median expression levels from the microarray data for each gene in Table II . There was no correlation between EFNA1 expression and clinicopathological factors including tumor size, vascular invasion and number of tumors. EPHA2 expression was not significantly correlated with any clinicopathological factors, except for microscopic portal invasion. Tumors with high expression of EPHA2 had a tendency to have microscopic vascular invasion, although this result was not statistically significant (p=0.0786) (Tables I and II) .
Correlation between EFNA1 and EPHA2 expression levels.
We next evaluated the correlation between EFNA1 and EphA2 expression levels using microarray data. We found that EFNA1 expression levels were significantly correlated with those of EPHA2 (Fig. 2) .
EFNA1 expression measured by quantitative RT-PCR correlated with microarray data.
We next examined the correlation between expression data from the microarray and quantitative RT-PCR (qRT-PCR) analysis of EFNA1 to validate the microarray data. qRT-PCR analysis was performed on 53 HCC tissue samples that were randomly selected from among the 139 HCC tissue specimens. Individual mRNA levels were normalized to GAPDH. In the 53 samples, qRT-PCR data for EFNA1 were significantly correlated with the results obtained from the microarray data (Fig. 3) .
Survival analysis stratified by EFNA1 and EPHA2 mRNA expression. Kaplan-Meier survival curves demonstrated that patients with high EFNA1 expression had significantly shorter disease-free survival (DFS) than those with low EFNA1 expression based on both microarray (Fig. 4A ) and qRT-PCR (Fig. 4B ) data. EPHA2 expression was not correlated with the prognosis for HCC after curative resection (Fig. 4C) . Univariate analysis for survival revealed that tumor number, microscopic vascular invasion, microscopic intrahepatic metastasis, and EFNA1 expression were significantly associated with DFS based on microarray data (Table III) . Multivariate Cox regression analysis clarified that only EFNA1 expression remained an independent prognostic factor (Table IV) .
Discussion
EFNA1 expression was previously reported to be associated with prognosis in early squamous cell cervical carcinoma (31) and colorectal cancer (32). However, the prognostic impact of EFNA1 in HCC patients remains unknown. The present study induces local hypoxia in advanced stages. Angiogenesis is an essential process in carcinogenesis and progression, and several angiogenic factors play important roles in HCC. We previously reported that the expression of vascular endothelial growth factor (VEGF) and angiopoietin-2 is associated with microvascular density in HCC. We also found that high nuclear expression of HIF1A is a significant predictive factor for recurrence after curative resection in HCC patients (9) . HIF1A is one of the key transcription factors induced by hypoxic conditions. In the absence of oxygen, it binds to hypoxia-response elements, which activates the expression of numerous hypoxia-response genes, such as VEGF, glucose transporter-1, erythropoietin and EFNA1 (33) . Two previous studies evaluated the association between expression of EFNA1 and clinical features in patients with HCC. One report revealed that expression of EFNA1 and AFP was strongly associated and that they induced the expression of genes related to the cell cycle, angiogenesis and cell-cell interactions (34) . The other report showed that EFNA1 mRNA was overexpressed in 90% of HCC cells and EPHA2 expression was significantly correlated with poor survival in HCC patients (35) . Both reports indicated that EFNA1 and its receptor, EphA2, promote proliferation and invasiveness in HCC.
Our result show that EFNA1 mRNA expression was significantly associated with EPHA2 mRNA expression, based on microarray data. Moreover, EFNA1 was a novel independent prognostic factor for HCC. However, EPHA2 was not a significant prognostic factor. EPHA2 is a transmembrane receptor tyrosine kinase that is frequently overexpressed in various cancers and is stimulated and phosphorylated by EFNA1 (36) (37) (38) . Overexpression of EPHA2 is associated with aggressive phenotypes and decreased differentiation (37, 39) . Our results also show EPHA2 expression tends to correlate with microscopic portal invasion. However, there was no association between EPHA2 and prognosis in HCC.
In the present study, we used tissue microarrays to analyze not only tumor cells, but also many vascular endothelial cells. EFNA1 ligand and its receptor, EPHA2, were expressed and upregulated in both tumor cells and tumor vessels. In line with the results of the present study, hypoxic conditions are known to upregulate the expression of EFNA1 in hepatoma cells in vitro (34, 35) . We previously reported that silencing of EFNA1 in tumor cells inhibits the migration, invasion and proliferation of tumor cells themselves and also inhibits the migration of endothelial cells in coculture experiment (32) . Thus, EFNA-mediated interactions between the endothelium and surrounding cells may be critical for vascular sprouting and the penetration of vessels into tumor tissues.
In conclusion, the present findings strongly suggest that EFNA1 expression is a useful marker for predicting a high risk of recurrence in HCC patients who have undergone curative resection. Anticancer treatments that target EFNA1 and EPHA2 may be particularly effective, because they could both suppress tumor neovascularization and directly affect tumor cells. It will be critical to the development of novel anticancer therapies to distinguish the effects of inhibiting EFNA1/EPHA2 activity on tumor vasculature versus tumor cells.
